Literature DB >> 25210613

Efficacy and safety of a unique enteric-coated bicarbonate-buffered pancreatic enzyme replacement therapy in children and adults with cystic fibrosis.

Michael W Konstan1, Frank J Accurso2, Samya Z Nasr3, Richard C Ahrens4, Gavin R Graff5.   

Abstract

BACKGROUND: Pancreatic enzyme replacement therapy (PERT) is used to treat exocrine pancreatic insufficiency in cystic fibrosis. RESULTS/
METHODS: Efficacy and safety of a unique enteric-coated (EC) bicarbonate-buffered PERT product (PERTZYE®/PANCRECARB®; Digestive Care, Inc., Bethlehem, PA, USA) was studied in a randomized, double-blind, placebo-controlled cross-over design. Subjects were stabilized on EC-bicarbonate-buffered PERT and a high-fat diet. During two treatment periods, subjects were randomized to EC-bicarbonate-buffered PERT or placebo, followed by a 72-h stool collection employing an ingested stool dye marker. Mean coefficient of fat absorption with EC-bicarbonate-buffered PERT was 82.5% compared with 46.3% with the placebo (absolute difference 36.2%; p < 0.001), a 78.2% improvement for active over placebo. Similar improvements in nitrogen absorption were observed. Overall stool frequency and stool weight decreased (p < 0.001). No safety concerns were identified.
SUMMARY: EC-bicarbonate-buffered PERT is effective in treating cystic fibrosis-associated exocrine pancreatic insufficiency.

Entities:  

Keywords:  bicarbonate-buffered pancrelipase; coefficient of fat absorption; cystic fibrosis; exocrine pancreatic insufficiency; pancreatic enzyme replacement therapy

Year:  2013        PMID: 25210613      PMCID: PMC4157687          DOI: 10.4155/cli.13.62

Source DB:  PubMed          Journal:  Clin Investig (Lond)        ISSN: 2041-6792


  17 in total

1.  Identification of transport abnormalities in duodenal mucosa and duodenal enterocytes from patients with cystic fibrosis.

Authors:  V S Pratha; D L Hogan; B A Martensson; J Bernard; R Zhou; J I Isenberg
Journal:  Gastroenterology       Date:  2000-06       Impact factor: 22.682

Review 2.  Gastrointestinal outcomes and confounders in cystic fibrosis.

Authors:  Drucy Borowitz; Peter R Durie; Lane L Clarke; Steven L Werlin; Christopher J Taylor; John Semler; Robert C De Lisle; Peter Lewindon; Steven M Lichtman; Maarten Sinaasappel; Robert D Baker; Susan S Baker; Henkjan J Verkade; Mark E Lowe; Virginia A Stallings; Morteza Janghorbani; Ross Butler; James Heubi
Journal:  J Pediatr Gastroenterol Nutr       Date:  2005-09       Impact factor: 2.839

3.  A breath of fresh air.

Authors:  Steven M Rowe; J P Clancy; Eric J Sorscher
Journal:  Sci Am       Date:  2011-08       Impact factor: 2.142

Review 4.  Cystic fibrosis.

Authors:  P B Davis; M Drumm; M W Konstan
Journal:  Am J Respir Crit Care Med       Date:  1996-11       Impact factor: 21.405

5.  Critical examination of therapeutic efficacy of a pH-sensitive enteric-coated pancreatic enzyme preparation in treatment of exocrine pancreatic insufficiency secondary to cystic fibrosis.

Authors:  S K Dutta; V S Hubbard; M Appler
Journal:  Dig Dis Sci       Date:  1988-10       Impact factor: 3.199

6.  Study design considerations for evaluating the efficacy and safety of pancreatic enzyme replacement therapy in patients with cystic fibrosis.

Authors:  Michael W Konstan; Drucy Borowitz; Nicole Mayer-Hamblett; Carlos Milla; Leslie Hendeles; Susan Murray; Richard A Kronmal; Susan Casey; Lynn M Rose; Wayne J Morgan; Bonnie W Ramsey
Journal:  Clin Investig (Lond)       Date:  2013-08

7.  Efficacy and safety of Creon 24,000 in subjects with exocrine pancreatic insufficiency due to cystic fibrosis.

Authors:  Bruce C Trapnell; Karen Maguiness; Gavin R Graff; David Boyd; Katrin Beckmann; Steven Caras
Journal:  J Cyst Fibros       Date:  2009-10-07       Impact factor: 5.482

8.  EUR-1008 pancreatic enzyme replacement is safe and effective in patients with cystic fibrosis and pancreatic insufficiency.

Authors:  Jamie L Wooldridge; James E Heubi; Rodolfo Amaro-Galvez; Steven R Boas; Kathryn V Blake; Samya Z Nasr; Barbara Chatfield; Susanna A McColley; Marlyn S Woo; Karen A Hardy; Richard M Kravitz; Cristina Straforini; Marco Anelli; Candace Lee
Journal:  J Cyst Fibros       Date:  2009-08-15       Impact factor: 5.482

9.  Efficacy and Safety of a New Formulation of Pancrelipase (Ultrase MT20) in the Treatment of Malabsorption in Exocrine Pancreatic Insufficiency in Cystic Fibrosis.

Authors:  Michael W Konstan; Theodore G Liou; Steven D Strausbaugh; Richard Ahrens; Jamshed F Kanga; Gavin R Graff; Kathryn Moffett; Susan L Millard; Samya Z Nasr; Edith Siméon; Jean Spénard; Josée Grondin
Journal:  Gastroenterol Res Pract       Date:  2010-12-08       Impact factor: 2.260

Review 10.  Evidence-based practice recommendations for nutrition-related management of children and adults with cystic fibrosis and pancreatic insufficiency: results of a systematic review.

Authors:  Virginia A Stallings; Lori J Stark; Karen A Robinson; Andrew P Feranchak; Hebe Quinton
Journal:  J Am Diet Assoc       Date:  2008-05
View more
  3 in total

1.  Study design considerations for evaluating the efficacy and safety of pancreatic enzyme replacement therapy in patients with cystic fibrosis.

Authors:  Michael W Konstan; Drucy Borowitz; Nicole Mayer-Hamblett; Carlos Milla; Leslie Hendeles; Susan Murray; Richard A Kronmal; Susan Casey; Lynn M Rose; Wayne J Morgan; Bonnie W Ramsey
Journal:  Clin Investig (Lond)       Date:  2013-08

2.  Pancreatic enzyme replacement therapy for people with cystic fibrosis.

Authors:  Usha Rani R Somaraju; Arturo Solis-Moya
Journal:  Cochrane Database Syst Rev       Date:  2020-08-05

Review 3.  Rapid therapeutic advances in CFTR modulator science.

Authors:  John P Clancy
Journal:  Pediatr Pulmonol       Date:  2018-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.